Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Penny Stocks With Promising Potential In December 2024

In This Article:

As December 2024 unfolds, global markets are experiencing a mixed bag of economic indicators, with U.S. consumer confidence dipping and major stock indexes showing moderate gains during the holiday-shortened week. Amidst these broader market dynamics, penny stocks—often associated with smaller or newer companies—continue to offer intriguing opportunities for investors seeking growth at lower price points. Despite being considered a niche area, when these stocks come with strong financial health and solid fundamentals, they present an underappreciated potential for significant returns.

Top 10 Penny Stocks

Name

Share Price

Market Cap

Financial Health Rating

DXN Holdings Bhd (KLSE:DXN)

MYR0.515

MYR2.56B

★★★★★★

Embark Early Education (ASX:EVO)

A$0.755

A$138.53M

★★★★☆☆

Datasonic Group Berhad (KLSE:DSONIC)

MYR0.415

MYR1.15B

★★★★★★

Hil Industries Berhad (KLSE:HIL)

MYR0.895

MYR297.09M

★★★★★★

MGB Berhad (KLSE:MGB)

MYR0.75

MYR443.74M

★★★★★★

Bosideng International Holdings (SEHK:3998)

HK$4.03

HK$44.38B

★★★★★★

LaserBond (ASX:LBL)

A$0.555

A$65.06M

★★★★★★

Begbies Traynor Group (AIM:BEG)

£0.926

£146.07M

★★★★★★

Lever Style (SEHK:1346)

HK$0.86

HK$545.92M

★★★★★★

Secure Trust Bank (LSE:STB)

£3.60

£68.66M

★★★★☆☆

Click here to see the full list of 5,829 stocks from our Penny Stocks screener.

Let's uncover some gems from our specialized screener.

Nanoform Finland Oyj

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Nanoform Finland Oyj provides nanotechnology and drug particle engineering services to the pharmaceutical and biotech industries in Europe and the United States, with a market cap of €108.62 million.

Operations: The company's revenue of €2.43 million is derived from its expertise in nanotechnology and drug particle engineering services.

Market Cap: €108.62M

Nanoform Finland Oyj, with a market cap of €108.62 million and revenue of €2.43 million, is focused on nanotechnology services for the pharmaceutical sector in Europe and the U.S. Despite its innovative niche, the company remains unprofitable with increasing losses over recent years. Revenue growth is projected at 55.7% annually; however, profitability isn't expected soon. Nanoform's financial stability is supported by a strong cash position covering liabilities and no debt burden, but shareholders have faced dilution as shares outstanding increased by 9%. The stock exhibits high volatility compared to most Finnish stocks.